Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Firsekibart - GeneScience Pharmaceuticals

Next Previous
Drug Profile

Firsekibart - GeneScience Pharmaceuticals

Alternative Names: Genakumab injection; GenSci 048

Latest Information Update: 14 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GeneScience Pharmaceuticals
  • Developer GeneScience Pharmaceuticals; Peking Union Medical College Hospital
  • Class Antigouts; Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Gouty arthritis
  • Phase II/III Juvenile rheumatoid arthritis
  • Phase II Interstitial lung diseases
  • Phase I Solid tumours

Most Recent Events

  • 06 May 2025 Changchun GeneScience Pharmaceutical plans a phase II trial for Endometriosis (In adults) in China(SC) in June 2025 (NCT06963177)
  • 10 Jan 2025 GeneScience Pharmaceuticals completes the phase I trial in Gouty arthritis in China (SC) (NCT06451848)
  • 20 Nov 2024 Efficacy data from a phase III GUARD-1 trial in Gout released by GeneScience Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top